Clinical Trials Logo

Filter by:
NCT ID: NCT05844137 Completed - Diabetes Mellitus Clinical Trials

Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes

NAFLD-DM
Start date: September 18, 2023
Phase: N/A
Study type: Interventional

The primary objective of this pilot study is to assess the feasibility and acceptability of an intervention for improved detection and evidence-based care of NAFLD in Latinx and Black patients with type 2 diabetes (T2D) in Duke University Healthcare system (DUHS). We will enroll 10-15 Latinx and 10-15 Black patients with T2D and NAFLD, based on having mildly elevated liver enzymes (ALT >/= 40 IU/mL in males, ALT >/= 31 IU/mL in females) and exclusion of other liver diseases (e.g., viral hepatitis, alcohol abuse). Intervention content will include: 1) NAFLD education; 2)diet/lifestyle support; 3) T2D medication management; and 4) clinically-indicated liver testing and care. Intervention feasibility will be evaluated by examining recruitment rates, retention rates, and study visit completion rates. Acceptability will be assessed by survey and through qualitative interviews. The project objectives and intervention are minimal risk. The expected risks will not exceed those of usual care.

NCT ID: NCT05844111 Completed - Healthy Volunteers Clinical Trials

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

Start date: May 22, 2023
Phase: Phase 1
Study type: Interventional

The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of [14C]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma, fecal and urinary elimination of total radioactivity.

NCT ID: NCT05844007 Completed - Clinical trials for Trauma and Stressor Related Disorders

A Trauma-Informed Intervention for Positive Youth Development and Teacher Wellness in Rural Montana Year 2

Start date: January 13, 2023
Phase: N/A
Study type: Interventional

Compared to U.S. urban counterparts, rural residents face major barriers to using health care services. Challenges include shortages of services, long distances to existing services, and stigma regarding mental illness in isolated communities. These difficulties hold true for Montana, but especially for adolescents. The objective of A Trauma-Informed Intervention for Positive Youth Development and Teacher Wellness in Rural Montana is to improve stress-related mental and physical health outcomes for adolescents and educators in rural Montana through school-based, trauma-informed yoga exercises. This project builds on investigators' previous research (including a two-year CAIRHE pilot study, 2019-21) to promote positive youth development by simultaneously intervening with students and teachers with a trauma-informed yoga intervention. Geographic isolation and resulting lack of resources for many Montanan schools indicates a need for novel, school-centered interventions to address the needs of rural adolescents; yoga can benefit youth and teacher wellbeing.

NCT ID: NCT05842967 Completed - Clinical trials for RESPIRATORY SYNCYTIAL VIRUS (RSV)

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

MONET
Start date: May 11, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn about the safety and immunogenicity of a study vaccine (called RSVpreF) in several adult groups. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies which help fight against diseases. This is called an immune response. This study will measure how much antibody participants make after receiving RSVpreF (immunogenicity). The study consists of 2 groups (Substudy A and Substudy B). Substudy A is seeking approximately 675 participants who are: - Between 18 and 60 years of age. - Considered having a high likelihood of severe RSV disease due to certain long-term medical conditions. Such medical conditions do not include immunocompromising conditions. Participants will need to come to the study clinic at least 2 times. At the first clinic visit, participants will receive 1 shot of RSVpreF or placebo in the arm by chance. A placebo looks like the study vaccine but contains no active ingredients. At each clinic visit, a blood sample will be taken. A third (final) visit can be either completed in clinic or via telephone contact. This study is about 6 months long for each participant. Substudy B is seeking approximately 200 participants who are: - At least 18 years of age. About half of the participants will be at least 60 years of age. - Considered having a weakened immune system (immunocompromised). Participants will need to come to the study clinic at least 3 times. All participants will receive a shot of RSVpreF at the first study clinic visit. The second study clinic visit will be 1 month later. All participants will receive a second shot of the study vaccine at this second study clinic visit. Blood samples will be taken at the 3 study clinic visits. A fourth (final) visit can be either completed in clinic or via telephone contact. This study is about 7 months long for each participant.

NCT ID: NCT05842460 Completed - Dietary Exposure Clinical Trials

Testing "Ultraprocessed" Front-of-package Label Among Brazilian Consumers

Start date: May 24, 2023
Phase: N/A
Study type: Interventional

The goal of this experiment is to test the effects an "ultraprocessed" warning label on foods and beverages among Brazilian consumers. The main questions it aims to answer are: - Do "ultraprocessed" warnings affect Brazilian consumers' intention to purchase products? - Do "ultraprocessed" warnings affect Brazilian consumers' product perceptions? Participants will see images of four products carrying either nutrient warning labels (which are currently mandatory in Brazil) or nutrient warning labels alongside an experimental warning label informing that the product is ultraprocessed. Participants will then answer survey questions about each product. Researchers will compare responses between both arms to determine if the "ultraprocessed" warning significantly changes the effect of nutrient warnings.

NCT ID: NCT05842434 Completed - Parkinson Disease Clinical Trials

Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor

Start date: June 6, 2023
Phase: N/A
Study type: Interventional

A prospective, open-label, multi-center pilot study designed to evaluate the safety and effectiveness of the Felix system in the relief of upper limb tremors in adults with essential tremor and Parkinson's disease.

NCT ID: NCT05842356 Completed - Stress Clinical Trials

Parental Feelings About Their Child Needing a Central Line

Start date: May 19, 2023
Phase: N/A
Study type: Interventional

The goal of this research project is to determine if different communication techniques during the consent process impact parental anxiety and comfort providing consent.

NCT ID: NCT05841277 Completed - Healthy Clinical Trials

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

Start date: April 25, 2023
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the amount of study drug (LY3819469) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3819469 will also be evaluated in these participants. The study will last up to 17 weeks including screening period.

NCT ID: NCT05841238 Completed - Healthy Clinical Trials

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Start date: April 26, 2023
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.

NCT ID: NCT05841160 Completed - QT/QTc Clinical Trials

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

Start date: March 15, 2023
Phase: Phase 1
Study type: Interventional

THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION